What is dMed Biopharmaceutical?
Caidya, formerly known as dMed Biopharmaceutical, serves as a global clinical research service provider that bridges the gap between biopharmaceutical innovation and clinical execution. With over two decades of industry experience, the firm specializes in delivering professional clinical trial expertise, utilizing a flexible, patient-centered approach to navigate the complexities of modern drug development. By maintaining a robust global presence, Caidya provides the infrastructure necessary for biopharma companies to reach diverse patient populations, ensuring that innovative breakthroughs are supported by rigorous, high-quality data collection and strategic clinical management.
How much funding has dMed Biopharmaceutical raised?
dMed Biopharmaceutical has raised a total of $158M across 3 funding rounds:
Series A
$8M
Series B
$50M
Series C
$100M
Series A (2016): $8M with participation from Zai Lab, Tairui Investment, and Qiming Venture Capital
Series B (2019): $50M led by Vivo Capital, Legend Capital, Lilly Asia Ventures, and Qiming Venture Partners
Series C (2020): $100M supported by Fidelity Management Services Inc, Kaiser Foundation Hospital, Sequoia Capital Operations LLC, and E Fund Management Co. Ltd
Key Investors in dMed Biopharmaceutical
Sequoia Capital Operations LLC
A globally renowned venture capital firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across the technology and healthcare sectors.
Qiming Venture Capital
A prominent venture capital firm focused on innovative companies in healthcare and technology, providing strategic guidance and industry resources to foster long-term growth.
Lilly Asia Ventures
A leading biomedical venture capital firm dedicated to partnering with exceptional entrepreneurs to develop breakthrough products that improve human health.
What's next for dMed Biopharmaceutical?
With the support of major institutional investors, Caidya is poised to further solidify its market position as a leader in clinical research services. The strategic focus moving forward involves deepening its technological integration to enhance trial agility and expanding its footprint in emerging markets. By aligning its service offerings with the evolving needs of global biopharmaceutical partners, the company is well-positioned to capitalize on the increasing demand for outsourced clinical expertise. The firm's ability to leverage its recent capital infusion will be pivotal in driving long-term value, fostering innovation, and ultimately accelerating the delivery of life-saving therapies to patients worldwide.
See full dMed Biopharmaceutical company page
